Delivery Order SPE2DB20D1109-SPE2DB25FP72Y
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,735.28 to AmerisourceBergen Drug Corp for Wezlana 90 mg/ml syringes. This firm fixed-price delivery order, issued on August 5, 2025, represents a non-competitive award executed under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 6,...
- The Defense Logistics Agency awarded a $33,133.71 delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Wezlana 90 mg/ml syringes. This firm fixed price delivery order, with an ultimate completion date of September 15, 2025, will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award was competitively procured with no set-aside designation. This delivery order is issued under AmerisourceBergen Drug Corp's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $23,540.76 to AmerisourceBergen Drug Corp for the supply of Wezlana 90 mg/mL syringes. This competitive delivery order, issued on August 7, 2025, with an ultimate completion date of August 8, 2025, utilizes firm fixed pricing and carries no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a major pharmaceutical distributor and critical federal...
- The Defense Logistics Agency awarded a delivery order valued at $15,763.91 to AmerisourceBergen Drug Corp for Wezlana 90 mg/ml syringes, with a completion date of September 15, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the Conshohocken, Pennsylvania-based pharmaceutical distributor. The product will be delivered to the place of performance in Conshohocken, PA. This delivery order represents a task order under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $82,826.37 to AmerisourceBergen Drug Corp for the supply of Wezlana 90 mg/ml syringes, with an ultimate completion date of September 9, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded on September 8, 2025. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $6,289.42 to AmerisourceBergen Drug Corp for the supply of Wezlana 90 mg/ml syringes. The contract, issued on July 31, 2025, with an ultimate completion date of August 1, 2025, utilizes firm fixed pricing and carries no set-aside designation, indicating it was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal...
- The Defense Logistics Agency awarded a $17,011.92 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Wezlana 90 mg/ml syringes. This firm fixed price contract, with an ultimate completion date of July 25, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The award was made through open competition with no set-aside designation...
- The Defense Logistics Agency awarded a delivery order valued at $11,343.96 to AmerisourceBergen Drug Corp for Wezlana 90 mg/mL syringes, with a completion date of August 8, 2025. This competitive award (no set-aside used) was issued on August 7, 2025, under a firm fixed price contract type. The product will be delivered to the contractor's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office operations as a major pharmaceutical distributor supporting...
- The Defense Logistics Agency awarded a delivery order valued at $13,536.00 to AmerisourceBergen Drug Corp for the supply of Wezlana 90 mg/ml syringes. This firm fixed price, competitively awarded delivery order was issued on August 14, 2025, with an ultimate completion date of August 15, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, indicating open competition among qualified vendors. This...
- The Defense Logistics Agency awarded a $49,209.51 delivery order to AmerisourceBergen Drug Corp for Wezlana 90 mg/ml syringes, with an ultimate completion date of September 10, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded on September 9, 2025. AmerisourceBergen will perform the work from its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB25FP72YDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $37,615.99 to AmerisourceBergen Drug Corp for Wezlana 90 mg/mL syringes. This firm fixed price delivery order, issued on September 10, 2025, with an ultimate completion date of September 11, 2025, represents a non-competitive award under an existing contract vehicle. The work will be performed at AmerisourceBergen Drug Corp's corporate office location in Conshohocken, Pennsylvania. As a child order under a larger indefinite delivery contract (IDC), this delivery order enables the federal government to procure critical pharmaceutical supplies to support military healthcare operations and medical supply chain requirements. This delivery order is issued under AmerisourceBergen Drug Corp's substantial indefinite delivery contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly for military and veteran healthcare systems. The parent IDC serves as a comprehensive global pharmaceutical support vehicle, enabling the company to supply a vast range of pharmaceutical products and medical supplies across multiple therapeutic domains to support military healthcare programs worldwide. The company's federal contract portfolio demonstrates consistent capability in delivering competitively awarded medical supply contracts through firm fixed pricing arrangements with DLA.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $37.6k | 9/10/25 |